Reports Q1 revenue $11.9M, consensus $0.7M. Revenue includes an $8.0M development milestone payment upon Lilly’s submission of an investigational new drug application, $3.5M of recognized deferred revenue from our licensing and collaboration agreement with BeiGene, as well as $0.4 million in other research support payments. As of March 31, 2019, Zymeworks had $180.3M in cash and cash equivalents and short-term investments.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.